Steris Plc (NYSE:STE) VP John Adam Zangerle sold 3,650 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total value of $321,200.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Steris Plc (STE) traded up $0.73 during trading on Wednesday, hitting $88.26. The company had a trading volume of 315,900 shares, compared to its average volume of 473,760. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.18 and a current ratio of 2.80. The company has a market capitalization of $7,444.63, a P/E ratio of 22.56 and a beta of 1.31. Steris Plc has a one year low of $64.37 and a one year high of $93.39.
Steris Plc (NYSE:STE) last announced its earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing analysts’ consensus estimates of $0.95 by ($0.01). The business had revenue of $634.20 million for the quarter, compared to the consensus estimate of $629.02 million. Steris Plc had a net margin of 5.59% and a return on equity of 11.49%. Steris Plc’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.89 EPS. equities analysts predict that Steris Plc will post 4.06 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 20th. Investors of record on Wednesday, November 22nd will be issued a dividend of $0.31 per share. The ex-dividend date is Tuesday, November 21st. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.40%. Steris Plc’s dividend payout ratio is presently 73.81%.
ILLEGAL ACTIVITY WARNING: This piece was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://stocknewstimes.com/2017/11/15/john-adam-zangerle-sells-3650-shares-of-steris-plc-ste-stock.html.
A number of analysts have recently weighed in on the company. TD Securities increased their price objective on Steris Plc from C$14.00 to C$16.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Raymond James Financial, Inc. increased their price objective on Steris Plc from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, October 16th. BidaskClub lowered Steris Plc from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research lowered Steris Plc from a “buy” rating to a “sell” rating in a research note on Monday, November 6th. Finally, KeyCorp restated an “overweight” rating and set a $101.00 target price (up previously from $91.00) on shares of Steris Plc in a report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Steris Plc currently has an average rating of “Hold” and a consensus price target of $77.80.
Institutional investors have recently made changes to their positions in the stock. Zions Bancorporation bought a new position in shares of Steris Plc during the third quarter valued at approximately $178,000. Citigroup Inc. bought a new position in shares of Steris Plc during the second quarter valued at approximately $206,000. Van Cleef Asset Management Inc bought a new position in shares of Steris Plc during the second quarter valued at approximately $208,000. Cigna Investments Inc. New bought a new position in shares of Steris Plc during the second quarter valued at approximately $209,000. Finally, BT Investment Management Ltd bought a new position in shares of Steris Plc during the second quarter valued at approximately $210,000. Institutional investors own 93.50% of the company’s stock.
About Steris Plc
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.